Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Department of Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
Eur Radiol. 2024 Oct;34(10):6831-6842. doi: 10.1007/s00330-024-10678-8. Epub 2024 Mar 22.
This study aimed to construct a radiomics-based model for prognosis and benefit prediction of concurrent chemoradiotherapy (CCRT) versus intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) following induction chemotherapy (IC).
A cohort of 718 LANPC patients treated with IC + IMRT or IC + CCRT were retrospectively enrolled and assigned to a training set (n = 503) and a validation set (n = 215). Radiomic features were extracted from pre-IC and post-IC MRI. After feature selection, a delta-radiomics signature was built with LASSO-Cox regression. A nomogram incorporating independent clinical indicators and the delta-radiomics signature was then developed and evaluated for calibration and discrimination. Risk stratification by the nomogram was evaluated with Kaplan-Meier methods.
The delta-radiomics signature, which comprised 19 selected features, was independently associated with prognosis. The nomogram, composed of the delta-radiomics signature, age, T category, N category, treatment, and pre-treatment EBV DNA, showed great calibration and discrimination with an area under the receiver operator characteristic curve of 0.80 (95% CI 0.75-0.85) and 0.75 (95% CI 0.64-0.85) in the training and validation sets. Risk stratification by the nomogram, excluding the treatment factor, resulted in two groups with distinct overall survival. Significantly better outcomes were observed in the high-risk patients with IC + CCRT compared to those with IC + IMRT, while comparable outcomes between IC + IMRT and IC + CCRT were shown for low-risk patients.
The radiomics-based nomogram can predict prognosis and survival benefits from concurrent chemotherapy for LANPC following IC. Low-risk patients determined by the nomogram may be potential candidates for omitting concurrent chemotherapy during IMRT.
The radiomics-based nomogram was constructed for risk stratification and patient selection. It can help guide clinical decision-making for patients with locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy, and avoid unnecessary toxicity caused by overtreatment.
• The benefits from concurrent chemotherapy remained controversial for locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy. • Radiomics-based nomogram achieved prognosis and benefits prediction of concurrent chemotherapy. • Low-risk patients defined by the nomogram were candidates for de-intensification.
本研究旨在构建一个基于放射组学的模型,用于预测接受诱导化疗(IC)后行局部区域晚期鼻咽癌(LANPC)调强放疗(IMRT)或同步放化疗(CCRT)的患者的预后和获益。
回顾性纳入了 718 例接受 IC+IMRT 或 IC+CCRT 治疗的 LANPC 患者,并将其分为训练集(n=503)和验证集(n=215)。从 IC 前和 IC 后 MRI 中提取放射组学特征。经过特征选择后,采用 LASSO-Cox 回归构建了一个差值放射组学特征模型。然后,我们构建了一个包含独立临床指标和差值放射组学特征的列线图,并对其进行校准和区分度评估。通过 Kaplan-Meier 方法评估列线图的风险分层。
包含 19 个选定特征的差值放射组学特征与预后独立相关。由差值放射组学特征、年龄、T 分期、N 分期、治疗方式以及治疗前 EBV DNA 组成的列线图在训练集和验证集中的校准度和区分度均较好,其受试者工作特征曲线下面积分别为 0.80(95%置信区间:0.75-0.85)和 0.75(95%置信区间:0.64-0.85)。排除治疗因素后,根据列线图进行风险分层,将患者分为两组,其总生存期存在明显差异。与接受 IC+IMRT 治疗的低危患者相比,高危患者接受 IC+CCRT 治疗的生存获益更好,而接受 IC+IMRT 和 IC+CCRT 治疗的中危患者之间的生存获益没有明显差异。
基于放射组学的列线图可以预测 LANPC 患者接受 IC 后同步化疗的预后和生存获益。列线图确定的低危患者可能是在 IMRT 中省略同步化疗的潜在候选人群。
本研究构建了一个基于放射组学的列线图,用于风险分层和患者选择。它可以帮助指导接受诱导化疗后局部区域晚期鼻咽癌患者的临床决策,避免过度治疗导致的不必要毒性。
接受诱导化疗后行局部区域晚期鼻咽癌同步放化疗的获益仍存在争议。
基于放射组学的列线图可预测同步化疗的预后和获益。
列线图定义的低危患者是减量化疗的候选人群。